https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-12-19 / Biotechnol. Lett. 2007 Mar;29(3):351-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-12-19 / Biotechnol. Lett. 2007 Mar;29(3):351-72006-12-19 00:00:002019-02-15 09:19:44Larger numbers of immature dendritic cells augment an anti-tumor effect against established murine melanoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):689-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):689-952006-11-01 00:00:002006-11-01 00:00:00Hyperthermia and immunity. A brief overview
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-14 / N. Engl. J. Med. 2006 Sep;355(11):1179-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-14 / N. Engl. J. Med. 2006 Sep;355(11):1179-812006-09-14 00:00:002019-02-15 09:19:46Patient-specific dendritic-cell vaccines for metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-572006-09-01 00:00:002019-02-15 09:19:45Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-16 / J Transl Med 2006 Aug;4:36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-16 / J Transl Med 2006 Aug;4:362006-08-16 00:00:002019-02-15 08:49:33Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-15 / Int. J. Cancer 2006 May;118(10):2617-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-15 / Int. J. Cancer 2006 May;118(10):2617-272006-05-15 00:00:002019-02-15 09:19:52Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-05 / Cancer Gene Ther. 2006 Oct;13(10):905-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-05 / Cancer Gene Ther. 2006 Oct;13(10):905-182006-05-05 00:00:002019-02-15 09:19:46Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-01 / Rev Recent Clin Trials 2006 May;1(2):87-102
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-01 / Rev Recent Clin Trials 2006 May;1(2):87-1022006-05-01 00:00:002019-02-15 09:19:28Dendritic cell immunotherapy for melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-03-01 / Int. J. Oncol. 2006 Mar;28(3):585-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-03-01 / Int. J. Oncol. 2006 Mar;28(3):585-932006-03-01 00:00:002019-02-15 09:19:52Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-702006-01-17 00:00:002019-02-15 09:19:51Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
